NLRP3 and metabolic dysfunction-associated steatotic liver disease: Apigenin has demonstrated potential in alleviating non-alcoholic fatty liver disease (NAFLD) and atherosclerosis by inhibiting NLRP3 inflammasome activation in mice with high-fat diets [96].